Oxervate™ (cenegermin-bkbj) is an ophthalmic solution indicated for the treatment of moderate-to-severe neurotrophic...
Oxurion reports mixed results from Phase IIa DME study
Oxurion has reported top-line results from the Phase IIa clinical trial of THR-317 in combination with ranibizumab to treat diabetic macular edema (DME) patients.
Outlook Therapeutics closes enrolment in Phase III wet AMD study
Outlook Therapeutics has concluded the enrolment of patients in a Phase III clinical trial of ONS-5010 for the treatment of patients with wet age-related macular degeneration (wet AMD).
ProQR to study new drug candidate for retinitis pigmentosa
ProQR Therapeutics has announced plans to conduct a Phase I/II clinical trial to evaluate QR-1123 for the treatment of patients with autosomal dominant retinitis pigmentosa (adRP).
Kodiak’s anti-VEGF antibody yields positive data in Phase Ib study
Kodiak Sciences has reported positive interim findings from an ongoing Phase Ib clinical trial of its anti-VEGF antibody biopolymer conjugate, KSI-301, for the treatment of three eye disorders.
Allergan and Editas to assess in-vivo CRISPR editing to treat LCA10
Allergan and Editas Medicine have launched a new Phase I/II clinical trial to assess CRISPR-based experimental medicine AGN-151587 (EDIT-101) for the treatment of Leber congenital amaurosis 10 (LCA10).
Immunocore, Pulse Infoframe to launch global patient registry for Uveal Melanoma
Immunocore and Pulse Infoframe are set to partner with academic institutions to launch first global patient registry for uveal melanoma (UM).
Expert Insights: Diabetic Macular Edema – Eye Screenings will be Critical in Preventing Vision Loss
Ana Fernandez Menjivar, GlobalData Epidemiologist, examines the diabetic macular edema space in the latest Expert Insights
Luxturna (voretigene neparvovec) for the Treatment of Biallelic RPE65 Mutation-Associated Retinal Dystrophy
LuxturnaTM (voretigene neparvovec) is approved for the treatment of patients with biallelic RPE65 mutation-associated retinal dystrophy.
Xiidra (lifitegrast ophthalmic solution) for the Treatment of Dry Eye Disease
Xiidra lifitegrast ophthalmic solution is a twice-a-day eye drop solution developed by Shire as a treatment for the signs and symptoms of dry eye disease in adults.